



# PBE Invesco Dynamic Biotechnology & Genome ETF



As of March 31, 2019

## Fund Description

The Invesco Dynamic Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex<sup>SM</sup> Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.


## Fund Data

Dynamic Biotechnology & Genome ETF	PBE
Intraday NAV (IIV)	PBEIV
Number of Securities	30
CUSIP	46137V787
Listing Exchange	NYSE Arca
30-Day SEC Yield	-0.38%
30-Day SEC Unsubsidized Yield	-0.38%
Total Expense Ratio	0.59%

## Underlying Index Data

Dynamic Biotech & Genome Intellidex Index Provider	DZOTR NYSE Arca
--	--------------------

## Growth of \$10,000



Data beginning 10 years prior to the ending date of March 31, 2019. Fund performance shown at NAV.

## Fund Performance & Index History (%)

	YTD	1 year	3 year	5 year	10 year	Fund Inception
<b>Underlying Index</b>						
Dynamic Biotech & Genome Intellidex Index	16.93	12.61	13.38	6.31	16.67	10.67
<b>Benchmark Index</b>						
S&P Composite 1500 Biotechnology Index	2.92	0.37	5.14	7.34	16.63	13.19
<b>Fund</b>						
NAV	16.77	12.26	13.35	6.36	16.23	10.34
Market Price	17.44	12.15	13.37	6.36	16.26	10.33

Returns less than one year are cumulative. Performance data quoted represents past performance. Past performance is not a guarantee of future results; current performance may be higher or lower than performance quoted. Investment returns and principal value will fluctuate and Shares, when redeemed, may be worth more or less than their original cost. See [invesco.com](http://invesco.com) to find the most recent month-end performance numbers. Market returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times. Fund performance reflects fee waivers, absent which, performance data quoted would have been lower.

## 10-Year Index Statistics

	Alpha	Beta	Correlation	Sharpe Ratio	Volatility (%)
Dynamic Biotech & Genome Intellidex Index	-	-	-	0.72	22.53
S&P Composite 1500 Biotechnology Index	1.48	0.96	0.82	0.84	19.33

Alpha, beta and correlation are that of the underlying index.

## A Smart Beta Portfolio

Fund Inception: June 23, 2005

Index returns do not represent Fund returns. An investor cannot invest directly in an index.

Neither the underlying Index nor the benchmark indexes charge management fees or brokerage expenses, and no such fees or expenses were deducted from the performance shown; nor do any of

the indexes lend securities, and no revenues from securities lending were added to the performance shown. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in the Fund.

The S&P Composite 1500<sup>®</sup> Biotech (S&P Biotech) Index consists of all biotechnology stocks included in

the S&P Composite 1500 Index.

Shares are not FDIC insured, may lose value and have no bank guarantee.

Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 50,000 Shares.

As of March 31, 2019

Top Fund Holdings (%)	
Name	Weight
Alnylam Pharmaceuticals	5.91
Celgene	5.13
Qiagen	5.06
Illumina	5.04
Amgen	4.94
Vertex Pharmaceuticals	4.84
Regeneron	4.73
Biogen	3.55
Veracyte	3.50
Akebia Therapeutics	3.32

Please see the website for complete holdings information. Holdings are subject to change.

Annual Index Performance (%)		
	Dynamic Biotech & Genome Intellidex Index	S&P Composite 1500 Biotechnology Index
2009	23.06	-5.35
2010	32.19	2.95
2011	-7.53	20.42
2012	14.84	41.26
2013	62.87	74.98
2014	36.56	32.78
2015	1.65	6.24
2016	-23.17	-12.93
2017	22.04	18.88
2018	0.55	-5.29
2019 YTD	16.93	2.92

Fund Details	
P/B Ratio	4.32
P/E Ratio	140.05
Return on Equity	6.64%
Weighted Market Cap (\$MM)	20,498

Fund Subindustry Allocations (%)	
Biotechnology	81.77
Life Sciences Tools & Services	12.79
Health Care Equipment	2.93
Pharmaceuticals	2.51

Fund Market-Cap Allocations (%)	
Large-Cap Blend	8.36
Large-Cap Growth	14.62
Large-Cap Value	4.94
Mid-Cap Blend	5.07
Mid-Cap Growth	22.31
Mid-Cap Value	2.67
Small-Cap Blend	2.46
Small-Cap Growth	36.08
Small-Cap Value	3.49

**About risk**

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund's return may not match the return of the Underlying Index. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.

The fund may engage in frequent trading of its portfolio securities in connection with the rebalancing or adjustment of the Underlying Index.

The Fund is non-diversified and may experience greater volatility than a more diversified investment.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

Investments focused in a particular industry, such as biotechnology and genome, are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

The **Intraday NAV** is a symbol representing estimated fair value based on the most recent intraday price of underlying assets. **Volatility** is the annualized standard deviation of index returns. **Sharpe Ratio** is a risk-adjusted measure calculated using standard deviation and excess return to determine reward per unit of risk.

A higher Sharpe Ratio indicates better risk-adjusted performance. **Correlation** indicates the degree to which two investments have historically moved in the same direction and magnitude. **Alpha** is a measure of performance on a risk-adjusted basis. **Weighted Harmonic Average Stock Price-to-Earnings Ratio (P/E Ratio)** is the share price divided by earnings per share. It is measured on a 12-month trailing basis. **Weighted Harmonic Average Stock Price-to-Book-Value Ratio (P/B Ratio)** is the ratio of a stock's market price to a company's net asset value. **Weighted Harmonic Average** is a method of calculating an average value that lessens the impact of large outliers and increases the impact of small ones. **Weighted Average Return on Equity** is net income divided by net worth. **Weighted Market Capitalization** is the sum of each underlying securities' market value. The **30-Day SEC Yield** is based on a 30-day period and is computed by dividing the net investment income per share earned during the period by the maximum offering price per share on the last day of the period. The **30-Day SEC Unsubsidized Yield** reflects the 30-day yield if the investment adviser were not waiving all or part of its fee or reimbursing the fund for part of its expenses. Total return would have also been lower in the absence of these temporary reimbursements or waivers. **Beta** is a measure of risk representing how a security is expected to respond to general market movements. **Smart Beta** represents an alternative and selection index based methodology that seeks to outperform a benchmark or reduce portfolio risk, or both. Smart beta funds may underperform cap-weighted

benchmarks and increase portfolio risk.

Typically, security classifications used in calculating allocation tables are as of the last trading day of the previous month.

The Global Industry Classification Standard was developed by and is the exclusive property and a service mark of MSCI, Inc. and Standard & Poor's.

The Intellidex™ Indexes are trademarks of NYSE Euronext or its affiliates and are licensed for use by Invesco Capital Management LLC in connection with the Invesco Intellidex investment products. The products are not sponsored or endorsed by NYSE Arca, and NYSE Arca makes no warranty or representation as to the accuracy and/or completeness of the Indexes or results to be obtained by any person from use of the Indexes or the trading of the products.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

**Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the fund, investors should ask their advisor(s) for a prospectus or download one at [invesco.com](http://invesco.com)**

Note: Not all products available through all firms or in all jurisdictions.